We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $143M
1-Year Est. Return 773.18%
This Fund
S&P 500
This Quarter Est. Return
+42.28%
1 Year Est. Return
+773.18%
3 Year Est. Return
+7,269.42%
5 Year Est. Return
+14,284.66%
10 Year Est. Return
+1,769,765.59%
AUM
$142M
AUM Growth
-$5.53M
Cap. Flow
-$27M
Cap. Flow %
-19.05%
Top 10 Hldgs %
77.36%
Holding
36
New
6
Increased
6
Reduced
13
Closed
9

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$4.19M
2
STRO icon
Sutro Biopharma
STRO
+$3.65M
3
DRUG
Bright Minds Biosciences
DRUG
+$2.22M
4
TNGX icon
Tango Therapeutics
TNGX
+$2.21M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$2.19M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$19.7M
2
TERN
Terns Pharmaceuticals
TERN
+$5.8M
3
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$4.93M
4
INSM icon
Insmed
INSM
+$4.5M
5
OCUL icon
Ocular Therapeutix
OCUL
+$4.39M

Sector Composition

Rank Sector Weight
1 Healthcare 97.59%
2 Miscellaneous 2.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PRAX icon
1
Praxis Precision Medicines
PRAX
$9.63B
$27.4M 19.3%
84,901
+1,865
+2% +$577K
TERN
2
DELISTED
Terns Pharmaceuticals
TERN
$26.1M 18.44%
495,772
-141,323
-22% -$5.8M
WHWK
3
Whitehawk Therapeutics
WHWK
$263M
$11.8M 8.3%
3,410,402
– –
TNGX icon
4
Tango Therapeutics
TNGX
$3.94B
$9.24M 6.52%
441,831
+159,099
+56% +$2.21M
DRUG
5
Bright Minds Biosciences
DRUG
$714M
$8.17M 5.77%
111,996
+27,519
+33% +$2.22M
STRO icon
6
Sutro Biopharma
STRO
$339M
$6.71M 4.73%
269,425
+201,974
+299% +$3.65M
ERAS icon
7
Erasca
ERAS
$6.31B
$5.74M 4.05%
+354,575
New +$4.19M
SRZN icon
8
Surrozen
SRZN
$264M
$5.04M 3.55%
172,847
-5,568
-3% -$133K
OCUL icon
9
Ocular Therapeutix
OCUL
$2.28B
$5.02M 3.54%
592,108
-460,887
-44% -$4.39M
CMPX icon
10
Compass Therapeutics
CMPX
$432M
$4.49M 3.17%
849,076
-244,224
-22% -$1.41M
NERV icon
11
Minerva Neurosciences
NERV
$231M
$4.27M 3.02%
709,500
– –
MLTX icon
12
MoonLake Immunotherapeutics
MLTX
$1.28B
$3.57M 2.52%
191,760
+132,480
+223% +$2.19M
ARGX icon
13
argenx
ARGX
$64B
$3.42M 2.42%
4,690
-161
-3% -$126K
OCS icon
14
Oculis Holding
OCS
$678M
$2.61M 1.84%
98,339
-3,438
-3% -$91K
RVMD icon
15
Revolution Medicines
RVMD
$44.6B
$2.54M 1.79%
26,069
+17,658
+210% +$1.78M
AMLX icon
16
Amylyx Pharmaceuticals
AMLX
$3.87B
$2.1M 1.48%
151,067
-182,191
-55% -$2.56M
TSHA icon
17
Taysha Gene Therapies
TSHA
$1.88B
$1.96M 1.39%
439,464
-15,363
-3% -$71.4K
IDYA icon
18
IDEAYA Biosciences
IDYA
$3.87B
$1.61M 1.13%
+48,234
New +$1.62M
DSGN icon
19
Design Therapeutics
DSGN
$946M
$1.55M 1.1%
145,900
-5,006
-3% -$50.7K
UTHR icon
20
United Therapeutics
UTHR
$22.1B
$1.32M 0.93%
2,224
-72
-3% -$35.9K
IDYA icon
21
CALL
IDEAYA Biosciences
IDYA
$3.87B
$1.17M 0.82%
+350
New +$11.7K
TRDA icon
22
Entrada Therapeutics
TRDA
$273M
$1.13M 0.8%
+89,358
New +$1.02M
AVTX icon
23
Avalo Therapeutics
AVTX
$1.05B
$908K 0.64%
+60,808
New +$951K
LBRX
24
LB Pharmaceuticals
LBRX
$1.54B
$713K 0.5%
28,919
-1,081
-4% -$24.9K
MAZE
25
Maze Therapeutics
MAZE
$1.52B
$577K 0.41%
19,335
-665
-3% -$29.3K
1
2

Similar funds

FPC
Flax Pond Capital Falmouth, Massachusetts $143M AUM
WWM
Woodside Wealth Management Framingham, Massachusetts $144M AUM 22.2% 1-Year Est. Return
AVA
Atlas Venture Advisors Boston, Massachusetts $143M AUM 25.68% 1-Year Est. Return
BOM
Bank of Marin Novato, California $143M AUM 26.89% 1-Year Est. Return
PWM
Pathway Wealth Management Dallas, Texas $143M AUM
FF
Fox Financial Wyomissing, Pennsylvania $144M AUM 28.05% 1-Year Est. Return
JPT
Jordan Park Trust Portsmouth, New Hampshire $143M AUM 15.59% 1-Year Est. Return
BJF
Blue Jean Financial Albany, New York $144M AUM

Acuta Capital Partners's Q1 2026 Portfolio in Review

As of Q1 2026, Acuta Capital Partners held 36 positions worth $142M, down 3.8% from $147M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Acuta Capital Partners withdrew a net $27M in Q1 2026, closing 9 positions and reducing 13 holdings. Its most notable exit was Cidara Therapeutics, an estimated $19.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Acuta Capital Partners opened a new position in Erasca worth $5.74M.

  • Acuta Capital Partners's largest Q1 2026 buy was Erasca: 354,575 shares worth $5.74M.
  • Acuta Capital Partners added most to Sutro Biopharma in Q1 2026, an estimated $3.65M increase.
  • Acuta Capital Partners's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $5.8M.
  • Acuta Capital Partners fully exited Cidara Therapeutics in Q1 2026, selling an estimated $19.7M.
  • Acuta Capital Partners's ten largest holdings make up 77% of its $142M portfolio in Q1 2026.
  • Acuta Capital Partners opened 6 new positions and closed 9 in Q1 2026.
  • Acuta Capital Partners's portfolio value fell 3.8% quarter-over-quarter to $142M.

Based on Acuta Capital Partners's 13F filing for Q1 2026, filed 15 May 2026.